{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:54:48Z","timestamp":1762458888854,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012164","name":"National High-tech Research and Development Program","doi-asserted-by":"publisher","award":["303040073006"],"award-info":[{"award-number":["303040073006"]}],"id":[{"id":"10.13039\/501100012164","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.ejca.2010.12.004","type":"journal-article","created":{"date-parts":[[2011,1,24]],"date-time":"2011-01-24T01:46:28Z","timestamp":1295833588000},"page":"848-853","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases"],"prefix":"10.1016","volume":"47","clinical-trial-number":[{"clinical-trial-number":"nct00697619","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yuan-Yuan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Yun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Kun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2010.12.004_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399407000312","article-title":"Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments","volume":"9","author":"Tao","year":"2007","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.ejca.2010.12.004_b0010","first-page":"229","article-title":"Patterns of distant metastases in nasopharyngeal carcinoma","volume":"12","author":"Huang","year":"1996","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.ejca.2010.12.004_b0015","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000055743","article-title":"Distant metastases from nasopharyngeal cancer","volume":"63","author":"Chiesa","year":"2001","journal-title":"ORL J Otorhinolaryngol Relat Spec"},{"key":"10.1016\/j.ejca.2010.12.004_b0020","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/1097-0142(19860815)58:4<843::AID-CNCR2820580406>3.0.CO;2-M","article-title":"Carcinoma of the nasopharynx. An analysis of 91 cases and a comparison of differing treatment approaches","volume":"58","author":"Rahima","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2010.12.004_b0025","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/annonc\/mdi162","article-title":"Bisphosphonates in breast cancer","volume":"16","author":"Coleman","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.12.004_b0030","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1200\/JCO.2005.11.931","article-title":"Progress in the management of bone metastases: one continent at a time?","volume":"23","author":"Hortobagyi","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.12.004_b0035","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/00024669-200403060-00004","article-title":"The role of bisphosphonates in the treatment of skeletal complications of breast cancer","volume":"3","author":"El-Rayes","year":"2004","journal-title":"Am J Cancer"},{"key":"10.1016\/j.ejca.2010.12.004_b0040","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.2002.20.3.850","article-title":"Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status","volume":"20","author":"Costa","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.12.004_b0045","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1002\/1097-0142(20000615)88:12+<2919::AID-CNCR7>3.0.CO;2-Z","article-title":"Biochemical markers and skeletal metastases","volume":"88","author":"Demers","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2010.12.004_b0050","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0093-7754(01)90233-7","article-title":"Use of markers of bone turnover for monitoring bone metastases and the response to therapy","volume":"28","author":"Lipton","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2010.12.004_b0055","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1200\/JCO.1997.15.1.131","article-title":"Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy","volume":"15","author":"Vinholes","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.12.004_b0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/bjc.1988.194","article-title":"Biochemical prediction of response of bone metastases to treatment","volume":"58","author":"Coleman","year":"1988","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2010.12.004_b0065","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/clinchem\/45.8.1240","article-title":"Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases","volume":"45","author":"Berruti","year":"1999","journal-title":"Clin Chem"},{"key":"10.1016\/j.ejca.2010.12.004_b0070","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2010.12.004_b0075","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2009.27.15_suppl.6063","article-title":"A prospective, open-label, randomized phase II trial to evaluate the changes of bone resorption marker after administration of zoledronic acid (ZOL) in nasopharyngeal cancer (NPC) patients with bone metastases (BM)","volume":"27","author":"Zhao","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.12.004_b0080","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1002\/cncr.10522","article-title":"The clinical use of bone resorption markers in patients with malignant bone disease","volume":"94","author":"Coleman","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2010.12.004_b0085","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.12.004_b0090","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2010.12.004_b0095","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2010.12.004_b0100","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial \u2013 the zoledronic acid lung cancer and other solid tumors study group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910011780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910011780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:17:35Z","timestamp":1760732255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804910011780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S0959804910011780"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2010.12.004","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2011,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2010.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}